$1,000 Genome at Last?

Illumina says its newest sequencing system can churn out whole human genomes for $1,000 apiece.

Written byTracy Vence
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, DOE HUMAN GENOME PROJECTIllumina this week claimed to be the first company to achieve the coveted $1,000 genome. While introducing the firm’s new sequencing systems at the annual JP Morgan Healthcare Conference ongoing in San Francisco, CEO Jay Flatley said that, when used at scale, the new HiSeq X Ten system—which comprises 10 integrated sequencers—can process whole human genomes for $1,000 each. Flatley said that the new machine—which is currently limited to human genomes—can partially sequence five genomes per day and complete 16 whole genomes in just three days, MIT Technology Review reported.

The total price tag represents $800 for reagents, $135 for equipment depreciation over four years, and $65 for overhead, such as staff, according to a cost breakdown posted by Mick Waston, head of bioinformatics at Edinburgh Genomics, on his Opiniomics blog.

According to GenomeWeb Daily News, Illumina is only selling the HiSeq X machines in orders of a minimum 10, for a total cost starting at $10 million. The Seoul-based company Macrogen, Australia’s Garvan Institute of Medical Research, and the Broad Institute of MIT and Harvard placed the first three orders for the system.

“Over the next few years, we have an opportunity to learn as much about the genetics of human disease as we have learned in the history of medicine,” the Broad’s Eric ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies